Petros Pharmaceuticals, Inc. (PTPI) financial statements (2022 and earlier)

Company profile

Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23,848
Cash and cash equivalents23,848
Receivables2,455
Inventory, net of allowances, customer advances and progress billings520
Inventory520
Prepaid expense679
Other current assets110
Other undisclosed current assets2,931
Total current assets:30,543
Noncurrent Assets
Inventory, Noncurrent11,029
Operating lease, right-of-use asset476
Property, plant and equipment49
Intangible assets, net (including goodwill)25,293
Intangible assets, net (excluding goodwill)25,293
Total noncurrent assets:36,847
TOTAL ASSETS:67,390
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,957
Accrued liabilities11,957
Other liabilities261
Other undisclosed current liabilities18,762
Total current liabilities:30,980
Noncurrent Liabilities
Long-term debt and lease obligation405
Operating lease, liability405
Liabilities, other than long-term debt405
Other liabilities405
Other undisclosed noncurrent liabilities55
Total noncurrent liabilities:865
Total liabilities:31,845
Stockholders' equity
Stockholders' equity attributable to parent35,545
Common stock2
Additional paid in capital106,232
Accumulated deficit(70,689)
Total stockholders' equity:35,545
TOTAL LIABILITIES AND EQUITY:67,390

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues7,811
Cost of revenue
(Cost of Goods and Services Sold)
(1,600)
Gross profit:6,212
Operating expenses(24,260)
Operating loss:(18,048)
Interest and debt expense(369)
Loss from continuing operations before equity method investments, income taxes:(18,417)
Other undisclosed income from continuing operations before income taxes9,430
Net loss available to common stockholders, diluted:(8,987)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(8,987)
Comprehensive loss, net of tax, attributable to parent:(8,987)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: